Skip to content

Treatment of Mandibular Class II Furcation With Different Types of Biomaterials in Humans

Treatment of Mandibular Class II Furcation With Different Types of Biomaterials

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07738705
Enrollment
48
Registered
2026-07-31
Start date
2025-04-18
Completion date
2026-07-26
Last updated
2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Furcation Lesions

Brief summary

This randomized controlled clinical trial aims to determine which biomaterial combination yields superior clinical and tomographic outcomes in the treatment of mandibular class II furcation defects. In addition, modifications of gingival phenotype in the furcation area will be assessed.

Interventions

PROCEDURESurgical procedure using different types of biomaterials

Compared the results of using different combinations of NovaBone and allograft with a microderm or collagen membranes aiming to decrease or close the furcation lesion.

Sponsors

Lake Erie College of Osteopathic Medicine
Lead SponsorOTHER
Osteogenics Biomedical
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults diagnosed with Stage III or Stage IV periodontitis presenting with at least one mandibular molar with a Class II furcation defect requiring regenerative surgical treatment. * Ability and willingness to provide written informed consent. * Medically stable and able to undergo periodontal surgery. * Willingness to comply with all study procedures and follow-up visits.

Exclusion criteria

* Stage I or Stage II periodontitis. * Current smokers. * Uncontrolled diabetes mellitus. * Alcohol or substance use disorder. * Chronic inflammatory diseases requiring continuous anti-inflammatory therapy. * Current use of bisphosphonates or other medications associated with medication-related osteonecrosis of the jaw. * Current use of medications known to induce gingival enlargement. * Continuous use of systemic antibiotics or anti-inflammatory medications. * Pregnant or breastfeeding individuals. * Known allergy or hypersensitivity to the antibiotics, local anesthetics, or other study-related medications. * Medical conditions that, in the investigator's judgment, make the participant unsuitable for periodontal surgery or study participation.

Design outcomes

Primary

MeasureTime frameDescription
Horizontal Bone Gain (HBG).6 monthsCone-beam computed tomography (CBCT) measurements will be obtained at baseline and 6 months from the buccal or lingual bone edge to the deepest bone defect, measured horizontally. Sites will be classified as buccal or lingual and analyzed at the site level, first pooled and then separately. Change scores (6 months-baseline) will be assessed using the Shapiro-Wilk test. Within-group changes will be analyzed with paired t-tests or Wilcoxon signed-rank tests, as appropriate. Between-group comparisons of baseline values and 6-month changes will be performed using one-way ANOVA with Tukey's HSD or Kruskal-Wallis with Dunn's test (Holm adjustment). To account for multiple sites per participant, primary bone outcomes will be analyzed using linear mixed-effects models or generalized estimating equations when required. Statistical significance will be set at P\<0.05. Analyses will be performed in Python 3 (pandas, SciPy, statsmodels).

Secondary

MeasureTime frameDescription
Improvement of the Gingival Phenotype6 monthsMeasurements will be obtained at baseline and 6 months using combined cone-beam computed tomography (CBCT) and oral scan images to determine gingival tissue width 2 mm apical to the gingival margin. Sites will be classified as buccal or lingual and analyzed at the site level, first pooled and then separately. Change scores (6 months-baseline) will be assessed using the Shapiro-Wilk test. Within-group changes will be analyzed with paired t-tests or Wilcoxon signed-rank tests, as appropriate. Between-group comparisons of baseline values and 6-month changes will be performed using one-way ANOVA with Tukey's HSD or Kruskal-Wallis with Dunn's test (Holm adjustment). To account for multiple sites per participant, outcomes will be analyzed using linear mixed-effects models or generalized estimating equations when required. Statistical significance will be set at P\<0.05. Analyses will be performed in Python 3 (pandas, SciPy, statsmodels).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 1, 2026